Access Menu

Log in via Social



Glucose sensor, B2B, high margins. We aspire to be the "Intel inside" for wearable glucose sensing systems.

This company and others may be fundraising.

Login or signup to access deals.

Company Overview

Founded in 2013, Glucovation has developed a continuous glucose monitoring system (CGM) for the diabetic patient. CGM is the new technology replacing the old technology of blood glucose (BG) meters. The BG meter market is $40B and the CGM market is $1B with 30% CAGR.

Our CGM sensor is based on new sensing technology that is highly accurate, easy to use, and very low cost to manufacture, (high margins).

Glucovation has developed a novel CGM that addresses the deficiencies of the existing CGM systems. The main players currently in this market are chasing the triad of (1) high accuracy, (2) ease of use and (3) low cost to the patient, (which requires low manufacturing cost).

Our CGM system has been designed from the beginning to be highly accurate, easy to use and low cost to manufacture. We have (3) patents on our current technology and have obtained very good pre-clinical results. The market is very large, (greater than $1B), and growing fast, (CAGR ~ 30%). There are many companies, large and small, that are trying to enter this market. These potential strategic partners are insulin drug companies, insulin pump companies, blood glucose meter companies, medical device companies seeking entrance into this large and fast growing market, and other glucose sensing companies that desire a better sensor than their current products.

Our technology is developed and ready for confirmatory clinical trials. Our strategy is to obtain ISO certification, conduct clinical trials and file for regulatory approval. At the same time, we are cultivating relationships with potential strategic partners. Obtaining the right strategic partner(s), will allow us to leverage their existing infrastructure and go to market quickly.

Pitch Deck


  • Glucovation achieves consistently solid in-vivo results with high accuracy

    October, 2018
  • Glucovation achieves consistently solid in-vitro results

    September, 2018
  • Glucovation significantly improves sensor-build yields

    August, 2018
  • Glucovation develops Fused Membrane Technology™ (FMT) and files patent

    July, 2018
  • Glucovation halts clinical trials and refocuses on improving foundational sensor chemistry and sensor-build process

    December, 2017
  • Glucose sensor accuracy good but not good enough

    November, 2017
  • Glucovation conducts a series of clinical trials in China

    October, 2017
  • Glucovation obtains investment at a $20M valuation

    March, 2017
  • China Sun enters into Development Agreement

    March, 2016
  • China Sun invests in Glucovation at a $10M valuation

    September, 2015
  • Glucovation files three patents

    April, 2014
  • Founders form Glucovation to develop novel and superior CGM technology

    May, 2013